EICHORCondition: Relapsed/Refractory Acute Myeloid Leukemia · Sponsor: Base Therapeutics (Shanghai) Co., Ltd.
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
This description comes directly from the study's public registry record.
Jun Yan · 13817651474 · yanjun@basetherapeutics.com
Always discuss trial participation with your own doctor first.
| Shanghai Pudong Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06541444